Inpharma 1366 - 30 Nov 2002

■ TLK 286* shows promising antitumour activity invarious cancers, according to data from 3 phase IItrials presented at the EORTC/NCI/AACR** Symposiumon Molecular Targets and Cancer Therapeutics, heldrecently in Frankfurt, Germany. Patients had advancedcolorectal cancer (n = 73), ovarian cancer refractoryor resistant to platinum and paclitaxel therapy (36), oradvanced non-small-cell lung cancer (NSCLC)refractory or resistant to platinum and taxane-basedtherapy (51).123 All received TLK 286 every 3 weeksuntil disease progression. Overall median survival was6.1 months in the colorectal cancer trial, 9 months inthe NSCLC trial, and has not yet been reached andexceeds 16 months in the ovarian cancer trial.Corresponding values for durable disease stabilisationwere 33%, 51% and 35% of patients, respectively. TLK286 was generally well tolerated.* Telik; phase II for colorectal, ovarian, breast and non-small-celllung cancers** European Organisation for the Research and Treatment ofCancer/National Cancer Institute/American Association of CancerResearch

1. Telik Inc. Telik Announces Positive Results From Phase 2 Clinical Trial OfTLK286 in Refractory Colorectal Cancer. Media Release : 20 Nov 2002.Available from: URL: http://www.telik.com.

2. Telik Inc. Telik Presents Positive Data From Phase 2 Trial of TLK286 inPlatinum Refractory or Resistant Ovarian Cancer. Media Release : 20 Nov2002. Available from: URL: http://www.telik.com.

3. Telik Inc. Telik Presents Positive Data From Phase 2 Trial of TLK286 inPlatinum Refractory or Resistant Non-Small Cell Lung Cancer. MediaRelease : 20 Nov 2002. Available from: URL: http://www.telik.com.

800888659

1

Inpharma 30 Nov 2002 No. 13661173-8324/10/1366-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved